Strict adherence to SGLT2 inhibitors reduces cardiovascular hospitalizations and mortality in T2DM patients with heart failure, ACS, or those undergoing revascularization or cardiac surgery [45]. The gene discussed is SLC5A2; the disease is heart failure.